Cargando…

Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples

Objectives: To develop a rat model of intra-amniotic inflammation, characterized by the concentration of interleukin-6 in the amniotic fluid, induced by an ultrasound-guided transabdominal administration of lipopolysaccharide into individual gestational sacs. Methods: An ultrasound-guided transabdom...

Descripción completa

Detalles Bibliográficos
Autores principales: Stranik, Jaroslav, Kacerovsky, Marian, Sterba, Martin, Andrys, Ctirad, Abad, Cilia, Staud, Frantisek, Micuda, Stanislav, Soucek, Ondrej, Jacobsson, Bo, Musilova, Ivana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039461/
https://www.ncbi.nlm.nih.gov/pubmed/35496265
http://dx.doi.org/10.3389/fphar.2022.871193
_version_ 1784694134715449344
author Stranik, Jaroslav
Kacerovsky, Marian
Sterba, Martin
Andrys, Ctirad
Abad, Cilia
Staud, Frantisek
Micuda, Stanislav
Soucek, Ondrej
Jacobsson, Bo
Musilova, Ivana
author_facet Stranik, Jaroslav
Kacerovsky, Marian
Sterba, Martin
Andrys, Ctirad
Abad, Cilia
Staud, Frantisek
Micuda, Stanislav
Soucek, Ondrej
Jacobsson, Bo
Musilova, Ivana
author_sort Stranik, Jaroslav
collection PubMed
description Objectives: To develop a rat model of intra-amniotic inflammation, characterized by the concentration of interleukin-6 in the amniotic fluid, induced by an ultrasound-guided transabdominal administration of lipopolysaccharide into individual gestational sacs. Methods: An ultrasound-guided transabdominal intra-amniotic administration of lipopolysaccharide or phosphate-buffered saline (PBS) as control was performed in rats on embryonic day 18. Only accessible gestational sacs with precise recording of their positions were injected. Twenty-four hours later, individual amniotic fluid samples were collected from the gestational sacs of laparotomized animals. The gestational sacs were divided into four subgroups: (i) with lipopolysaccharide: injected gestational sacs from rats undergoing lipopolysaccharide administration; (ii) without lipopolysaccharide: non-injected gestational sacs from rats undergoing lipopolysaccharide administration; (iii) with PBS: injected gestational sacs from rats undergoing PBS administration; and (iv) without PBS: non-injected gestational sacs from rats undergoing PBS administration. The concentration of interleukin-6 in individual amniotic fluid samples was assessed using ELISA. Results: In the group of five animals receiving lipopolysaccharide, 24 (33%) and 48 (77%) gestational sacs were and were not injected, respectively. The amniotic fluid was obtained from 21 (88%) injected and 46 (95%) non-injected sacs. In the control group of five animals receiving phosphate-buffered saline, 28 (35%) and 52 (75%) gestational sacs were and were not injected, respectively. The amniotic fluid was obtained from 18 (64%) injected and 50 (96%) non-injected sacs. No labor occurred, and only one fetal death was observed in a gestational sac injected with lipopolysaccharide. Differences in concentrations of interleukin-6 in the amniotic fluid were found among the subgroups of the gestational sacs (with lipopolysaccharide: median 762 pg/ml; without lipopolysaccharide: median 35.6 pg/ml; with PBS: median 35.6 pg/ml; and without PBS: median 35.6 pg/ml; p < 0.0001). Concentrations of interleukin-6 in the amniotic fluid from the gestational sacs with lipopolysaccharide were significantly higher than those in the three remaining subgroups (p < 0.0001). No differences in concentrations of interleukin-6 in the amniotic fluid were identified between the three remaining subgroups. Conclusion: The ultrasound-guided transabdominal intra-amniotic administration of lipopolysaccharide with a subsequent collection and analysis of amniotic fluid samples is feasible in rats. The intra-amniotic administration of lipopolysaccharide led to the development of intra-amniotic inflammation without leading to fetal mortality or induction of labor.
format Online
Article
Text
id pubmed-9039461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90394612022-04-27 Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples Stranik, Jaroslav Kacerovsky, Marian Sterba, Martin Andrys, Ctirad Abad, Cilia Staud, Frantisek Micuda, Stanislav Soucek, Ondrej Jacobsson, Bo Musilova, Ivana Front Pharmacol Pharmacology Objectives: To develop a rat model of intra-amniotic inflammation, characterized by the concentration of interleukin-6 in the amniotic fluid, induced by an ultrasound-guided transabdominal administration of lipopolysaccharide into individual gestational sacs. Methods: An ultrasound-guided transabdominal intra-amniotic administration of lipopolysaccharide or phosphate-buffered saline (PBS) as control was performed in rats on embryonic day 18. Only accessible gestational sacs with precise recording of their positions were injected. Twenty-four hours later, individual amniotic fluid samples were collected from the gestational sacs of laparotomized animals. The gestational sacs were divided into four subgroups: (i) with lipopolysaccharide: injected gestational sacs from rats undergoing lipopolysaccharide administration; (ii) without lipopolysaccharide: non-injected gestational sacs from rats undergoing lipopolysaccharide administration; (iii) with PBS: injected gestational sacs from rats undergoing PBS administration; and (iv) without PBS: non-injected gestational sacs from rats undergoing PBS administration. The concentration of interleukin-6 in individual amniotic fluid samples was assessed using ELISA. Results: In the group of five animals receiving lipopolysaccharide, 24 (33%) and 48 (77%) gestational sacs were and were not injected, respectively. The amniotic fluid was obtained from 21 (88%) injected and 46 (95%) non-injected sacs. In the control group of five animals receiving phosphate-buffered saline, 28 (35%) and 52 (75%) gestational sacs were and were not injected, respectively. The amniotic fluid was obtained from 18 (64%) injected and 50 (96%) non-injected sacs. No labor occurred, and only one fetal death was observed in a gestational sac injected with lipopolysaccharide. Differences in concentrations of interleukin-6 in the amniotic fluid were found among the subgroups of the gestational sacs (with lipopolysaccharide: median 762 pg/ml; without lipopolysaccharide: median 35.6 pg/ml; with PBS: median 35.6 pg/ml; and without PBS: median 35.6 pg/ml; p < 0.0001). Concentrations of interleukin-6 in the amniotic fluid from the gestational sacs with lipopolysaccharide were significantly higher than those in the three remaining subgroups (p < 0.0001). No differences in concentrations of interleukin-6 in the amniotic fluid were identified between the three remaining subgroups. Conclusion: The ultrasound-guided transabdominal intra-amniotic administration of lipopolysaccharide with a subsequent collection and analysis of amniotic fluid samples is feasible in rats. The intra-amniotic administration of lipopolysaccharide led to the development of intra-amniotic inflammation without leading to fetal mortality or induction of labor. Frontiers Media S.A. 2022-04-12 /pmc/articles/PMC9039461/ /pubmed/35496265 http://dx.doi.org/10.3389/fphar.2022.871193 Text en Copyright © 2022 Stranik, Kacerovsky, Sterba, Andrys, Abad, Staud, Micuda, Soucek, Jacobsson and Musilova. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Stranik, Jaroslav
Kacerovsky, Marian
Sterba, Martin
Andrys, Ctirad
Abad, Cilia
Staud, Frantisek
Micuda, Stanislav
Soucek, Ondrej
Jacobsson, Bo
Musilova, Ivana
Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples
title Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples
title_full Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples
title_fullStr Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples
title_full_unstemmed Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples
title_short Development of a Rat Model of Intra-Amniotic Inflammation via Ultrasound-Guided Administration of a Triggering Agent in the Gestational Sac to Enable Analysis of Individual Amniotic Fluid Samples
title_sort development of a rat model of intra-amniotic inflammation via ultrasound-guided administration of a triggering agent in the gestational sac to enable analysis of individual amniotic fluid samples
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039461/
https://www.ncbi.nlm.nih.gov/pubmed/35496265
http://dx.doi.org/10.3389/fphar.2022.871193
work_keys_str_mv AT stranikjaroslav developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT kacerovskymarian developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT sterbamartin developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT andrysctirad developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT abadcilia developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT staudfrantisek developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT micudastanislav developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT soucekondrej developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT jacobssonbo developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples
AT musilovaivana developmentofaratmodelofintraamnioticinflammationviaultrasoundguidedadministrationofatriggeringagentinthegestationalsactoenableanalysisofindividualamnioticfluidsamples